comparemela.com
Home
Live Updates
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects : comparemela.com
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
SOUTH SAN FRANCISCO, Calif., April 03, 2024 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in...
Related Keywords
United States ,
Jordyn Tarazi ,
Michael Fitzhugh ,
Lawrence Blatt ,
Aligos Therapeutics Inc ,
Exchange Commission ,
Investor Relations Corporate Communications ,
Nasdaq ,
Exchange Commission On ,
Lifesci Communications ,
Chief Executive Officer ,
Securities Litigation Reform Act ,
Aligo Annual Report ,
Investor Relations ,
Markets ,
comparemela.com © 2020. All Rights Reserved.